(Q52571074)

English

Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccine.

scientific article published on 11 May 2006

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/16725238

Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccine. (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/16725238

0 references

1 reference

based on heuristic

inferred from title

7

object named as

Shibo Jiang

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/16725238

3

object named as

Lanying Du

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/16725238

6

object named as

Yusen Zhou

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/16725238

author name string

Yuxian He

1

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/16725238

Jingjing Li

2

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/16725238

Xuxia Yan

4

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/16725238

Guangan Hu

5

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/16725238

language of work or name

0 references

publication date

11 May 2006

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/16725238

number of pages

11

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/16725238

24

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/16725238

26

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/16725238

5498-5508

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/16725238

Identification of a novel coronavirus in patients with severe acute respiratory syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.054

7 January 2021

A novel coronavirus associated with severe acute respiratory syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.054

7 January 2021

The Genome sequence of the SARS-associated coronavirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.054

7 January 2021

Coronavirus as a possible cause of severe acute respiratory syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.054

7 January 2021

Characterization of a novel coronavirus associated with severe acute respiratory syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.054

7 January 2021

Virus detectives seek source of SARS in China's wild animals

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.054

7 January 2021

Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.054

7 January 2021

Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.054

7 January 2021

Bats are natural reservoirs of SARS-like coronaviruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.054

7 January 2021

Vaccine design for severe acute respiratory syndrome coronavirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.054

7 January 2021

SARS vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.054

7 January 2021

Medicine. Caution urged on SARS vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.054

7 January 2021

A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.054

7 January 2021

Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.054

7 January 2021

Immunogenicity of SARS inactivated vaccine in BALB/c mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.054

7 January 2021

Immune responses in Balb/c mice induced by a candidate SARS-CoV inactivated vaccine prepared from F69 strain

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.054

7 January 2021

Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.054

7 January 2021

Augmentation of immune responses to SARS coronavirus by a combination of DNA and whole killed virus vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.054

7 January 2021

Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.054

7 January 2021

Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.054

7 January 2021

Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.054

7 January 2021

Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.054

7 January 2021

A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.054

7 January 2021

The secret life of ACE2 as a receptor for the SARS virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.054

7 January 2021

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.054

7 January 2021

A model of the ACE2 structure and function as a SARS-CoV receptor.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.054

7 January 2021

Amino acids 270 to 510 of the severe acute respiratory syndrome coronavirus spike protein are required for interaction with receptor

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.054

7 January 2021

A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.054

7 January 2021

The SARS-CoV S glycoprotein: expression and functional characterization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.054

7 January 2021

Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.054

7 January 2021

Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.054

7 January 2021

An exposed domain in the severe acute respiratory syndrome coronavirus spike protein induces neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.054

7 January 2021

Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.054

7 January 2021

Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.054

7 January 2021

A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.054

7 January 2021

Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.054

7 January 2021

Structure of SARS coronavirus spike receptor-binding domain complexed with receptor

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.054

7 January 2021

Identification of two critical amino acid residues of the severe acute respiratory syndrome coronavirus spike protein for its variation in zoonotic tropism transition via a double substitution strategy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.054

7 January 2021

Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.054

7 January 2021

Single amino acid substitutions in the severe acute respiratory syndrome coronavirus spike glycoprotein determine viral entry and immunogenicity of a major neutralizing domain.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.054

7 January 2021

The SARS coronavirus S glycoprotein receptor binding domain: fine mapping and functional characterization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.054

7 January 2021

Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine

1 reference

https://pubmed.ncbi.nlm.nih.gov/16725238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.VACCINE.2006.04.054

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/16725238

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/16725238

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q52571074&oldid=1775336380"